Identification of Membrane-expressed CAPRIN-1 as a Novel and Universal Cancer Target, and Generation of a Therapeutic Anti-CAPRIN-1 Antibody TRK-950.
Fumiyoshi Okano, Takanori Saito, Yoshitaka Minamida...
https://pubmed.ncbi.nlm.nih.gov/37082579/Actively Recruiting
Led by Toray Industries, Inc · Updated on 2026-10-08
49
Participants Needed
10
Research Sites
N/A
Total Duration
Researchers are investigating TRK-950 in patients with advanced solid tumors and melanoma in an open-label phase III study. The study aims to assess the safety and tolerability of TRK-950 alone or in combination with nivolumab in patients with advanced solid tumors, and to evaluate the efficacy of TRK-950 in patients with advanced or recurrent unresectable melanoma who have previously received chemotherapy with dacarbazine and have no standard treatment options. The study includes three parts Part 1 administers two dose levels of TRK-950 to patients with advanced solid tumors refractory or intolerant to standard therapies Part 2 gives two dose levels of TRK-950 combined with nivolumab, with nivolumab dosed at 240 mg intravenously every two weeks Part 3 treats melanoma patients with one dose level of TRK-950. TRK-950 is given intravenously on days 1, 8, 15, and 22 of a 28-day cycle in most parts, with variations in dosing schedules depending on the part and combination with nivolumab. Participants will receive intravenous infusions of study drugs according to their assigned part and dose level. Researchers will monitor safety through dose-limiting toxicities, adverse events, and serious adverse events for up to one year. Pharmacokinetic profiles and antibody development against TRK-950 will be assessed. In Part 3, efficacy will be measured by response rates and survival outcomes over approximately 12 months. The study duration spans from initial dosing through follow-up assessments up to study completion in March 2028.
CONDITIONS
A Study of TRK-950 in Patients With Advanced Solid Tumors
T
Toray Contact for Clinical Trial Information
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Toray Industries, Inc
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 12 months
Participants receive TRK-950 alone or in combination with nivolumab by intravenous infusion on specified days within 28-day cycles.
Regular visits during treatment cycles
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
4
Have more questions? Get in touch with our team for quick support
Fumiyoshi Okano, Takanori Saito, Yoshitaka Minamida...
https://pubmed.ncbi.nlm.nih.gov/37082579/Takafumi Koyama, Kan Yonemori, Jun Sato...
https://pubmed.ncbi.nlm.nih.gov/41979863/Toray Industries, Inc
Lead Sponsor